Amphastar Pharmaceuticals (NASDAQ:AMPH) Research Coverage Started at Barclays

Barclays assumed coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note published on Tuesday morning, Marketbeat reports. The firm issued an equal weight rating and a $30.00 target price on the stock.

Several other research firms also recently commented on AMPH. Zacks Research downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 14th. Bank of America increased their price objective on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Needham & Company LLC dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 1st. Two investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average price target of $31.00.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $25.90 on Tuesday. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $45.39. The business’s fifty day moving average is $25.55 and its 200-day moving average is $25.65. The company has a market cap of $1.19 billion, a P/E ratio of 11.46, a price-to-earnings-growth ratio of 7.20 and a beta of 0.91.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. The company had revenue of $191.84 million for the quarter, compared to analysts’ expectations of $186.90 million. Equities research analysts forecast that Amphastar Pharmaceuticals will post 3.49 EPS for the current year.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 4,179 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the transaction, the director owned 35,183 shares in the company, valued at approximately $953,459.30. This represents a 10.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Floyd F. Petersen sold 16,679 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $26.49, for a total value of $441,826.71. Following the transaction, the director owned 75,531 shares of the company’s stock, valued at $2,000,816.19. This represents a 18.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 21,858 shares of company stock valued at $581,313 in the last 90 days. Company insiders own 27.50% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals by 356.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock valued at $25,000 after acquiring an additional 737 shares during the last quarter. Global Retirement Partners LLC lifted its stake in shares of Amphastar Pharmaceuticals by 219.0% in the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock valued at $27,000 after purchasing an additional 703 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in Amphastar Pharmaceuticals by 192.8% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock worth $29,000 after buying an additional 831 shares in the last quarter. Hantz Financial Services Inc. grew its position in Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after buying an additional 1,338 shares during the period. Finally, Quarry LP purchased a new position in Amphastar Pharmaceuticals in the third quarter valued at $32,000. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.